Comparison of anlotinib versus bevacizumab combined with paclitaxel and carboplatin in treatment of advanced lung adenocarcinoma
Meng Lingxin
Zeng Qinqin
Meng Qin
Zheng Yuxiu
Xu Meiling
Li Bingcheng
Wu Haiying
Zhou Dandan
Abstract：Objective To investigate the short-term efficacy and safety of anlotinib and bevacizumab combined with paclitaxel and carboplatin in the treatment of advanced lung adenocarcinoma.Methods A retrospective analysis was performed on 136 patients with advanced lung adenocarcinoma(stage ⅢB or Ⅳ) admitted to People's Hospital of Rizhao from June 2017 to June 2018.Among them,64 patients were treated with paclitaxel/carboplatin chemotherapy (chemotherapy group);34 patients were treated with anlotinib + paclitaxel/carboplatin chemotherapy (anlotinib group);38 patients were treated with bevacizumab + paclitaxel/carboplatin chemotherapy(bevacizumab group).Short-term efficacy,adverse reactions and levels of tumor markers [vascular endothelial growth factor (VEGF),carcinoembryonic antigen(CEA) and neuron-specific enolase(NSE)] were analyzed.Results Objective remission rate and disease control rate in anlotinib group and bevacizumab group were significantly higher than those in chemotherapy group[67.6％ (23/34),50.0％ (19/38) vs 20.3％ (13/64);79.4％ (27/34),65.8％(25/38) vs 39.1％ (25/64)] (all P ＜ 0.05).Objective remission rate and disease control rate in anlotinib group were significandy higher than those in bevacizumab group(P =0.022,0.016).There was no significant difference in the incidence of common adverse reactions among the three groups(all P ＞ 0.05).Before treatment,there was no significant difference in the levels of VEGF,CEA and NSE among the three groups (all P ＞ 0.05).After treatment,the levels of tumor markers significantly decreased and they were significantly lower in anlotinib group and bevacizumab group than those in chemotherapy group[(303 ± 64),(336 ± 71) ng/L vs (416 ± 69) ng/L;(6±4),(8 ±4)μg/Lvs (12 ±4)μg/L;(14.4 ±4.6),(16.2 ±3.7)μg/L vs (20.3 ±2.7)μg/L](all P＜0.05).Conclusions Anlotinib and bevacizumab combined with paclitaxel/carboplatin chemotherapy show definite efficacy in the treatment of advanced lung adenocarcinoma.Both regimens are effective,safe and well tolerated in improving objective remission rate and disease control rate,reduce the levels of VEGF,CEA and NSE.
Keywords：Lung adenocarcinomaAnlotinibBevacizumabPaclitaxelAnti-angiogenesis
Publication Date：2019-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 1164-1168 )